Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963025 | 0.88 | TRPM8 (0.63) | RAB9ANPC1SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3960796 | 0.83 | TRPM8 (0.48) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL3956812 | 0.81 | PPARA (0.45) | RAB9ANPC1SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3961372 | 0.81 | FFAR1 (0.47) | SMN1; SMN2ALDH1A1POLBTRPM8TDP1 | |
| SCHEMBL3959641 | 0.81 | TRPM8 (0.46) | SMN1; SMN2ALDH1A1TRPM8L3MBTL1 | |
| SCHEMBL3963639 | 0.79 | TRPM8 (0.51) | RAB9ANPC1ALDH1A1TRPM8 | |
| SCHEMBL3960751 | 0.79 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL3956893 | 0.79 | TP53 (0.50) | SMN1; SMN2ALDH1A1TRPM8GAA | |
| SCHEMBL3963786 | 0.79 | FFAR1 (0.49) | RAB9ASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3967726 | 0.78 | ALOX5 (0.42) | RAB9ANPC1KMT2AMEN1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | RAB9A 1893/4885NPC1 14/4885SMN1; SMN2 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.